Pancreatic Cancer
Specialty Channel

Featured Article
Jordan Berlin, MD, shares an overview of new treatment options and trials in pancreatic cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Long-term outcomes of the ESPAC-4 trial showed improved survival and slightly less toxicity with adjuvant gemcitabine plus capecitabine versus gemcitabine alone for resected pancreatic cancer.
Anetumab ravtansine yielded manageable safety and encouraging antitumor activity in a study of heavily pretreated patients with mesothelin-expressing solid tumors.
The FDA has approved pemigatinib for the treatment of adults with certain types of pretreated, advanced cholangiocarcinoma.
Molecularly-matched treatments significantly increased OS in patients with pancreatic cancer and actionable molecular alteration in a retrospective Know Your Tumor registry analysis.
A link exists between disease progression and reduced QoL in patients with metastatic breast, pancreatic, lung, and colorectal cancers.

News

At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Long-term outcomes of the ESPAC-4 trial showed improved survival and slightly less toxicity with adjuvant gemcitabine plus capecitabine versus gemcitabine alone for resected pancreatic cancer.

Interactive Features

Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
Stay in the know.
OncNet Newsletter